PMID- 35347028
OWN - NLM
STAT- MEDLINE
DCOM- 20220404
LR  - 20220531
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 42
IP  - 4
DP  - 2022 Apr
TI  - Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin's Lymphoma 
      Receiving ESHAP+/-R Therapy.
PG  - 2053-2060
LID - 10.21873/anticanres.15686 [doi]
AB  - BACKGROUND/AIM: The occurrence of chemotherapy-related serious adverse events 
      (AEs) is associated with a poor prognosis of hematopoietic malignancies. We have 
      developed a medication guidance sheet (MGS) for monitoring AEs occurring when 
      combining chemotherapy with etoposide, methylprednisolone, cisplatin, cytarabine, 
      and rituximab (ESHAP+/-R). In this study, the usefulness of MGS was investigated in 
      non-Hodgkin's lymphoma patients. PATIENTS AND METHODS: The MGS was used to 
      monitor AEs in 48 adult patients receiving ESHAP+/-R. The prediction accuracy of 
      the MGS was estimated before and after modification based on practical data. 
      RESULTS: A total of 246 AEs developed, all of which were predicted by the MGS. 
      Among them, 149 events (61%) occurred during the same period as those predicted 
      by the MGS. After modification of MGS for the onset and duration of AEs, the 
      accuracy increased to 84%. CONCLUSION: The accuracy of the original MGS for 
      ESHAP+/-R was insufficient but greatly improved after the AEs duration 
      modification.
CI  - Copyright (c) 2022 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Uchida, Mayako
AU  - Uchida M
AD  - Education and Research Center for Clinical Pharmacy, Osaka University of 
      Pharmaceutical Sciences, Osaka, Japan; m-uchida@dwc.doshisha.ac.jp.
AD  - Department of Education and Research Center for Pharmacy Practice, Faculty of 
      Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyoto, Japan.
FAU - Murata, Saeko
AU  - Murata S
AD  - Department of Education and Research Center for Pharmacy Practice, Faculty of 
      Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyoto, Japan.
FAU - Morikawa, Hanae
AU  - Morikawa H
AD  - Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan.
FAU - Yonemitsu, Hiroko
AU  - Yonemitsu H
AD  - Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan.
FAU - Ishida, Shigeru
AU  - Ishida S
AD  - Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan.
FAU - Suetsugu, Kimitaka
AU  - Suetsugu K
AD  - Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan.
FAU - Tsuji, Toshikazu
AU  - Tsuji T
AD  - Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan.
FAU - Watanabe, Hiroyuki
AU  - Watanabe H
AD  - Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan.
AD  - Department of Pharmacy, Fukuoka Tokushukai Hospital, Fukuoka, Japan.
FAU - Kawashiri, Takehiro
AU  - Kawashiri T
AD  - Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of 
      Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
FAU - Kato, Koji
AU  - Kato K
AD  - Department of Medicine and Biosystemic Science, Kyushu University Graduate School 
      of Medical Sciences, Fukuoka, Japan.
FAU - Hosohata, Keiko
AU  - Hosohata K
AD  - Education and Research Center for Clinical Pharmacy, Osaka University of 
      Pharmaceutical Sciences, Osaka, Japan.
FAU - Miyamoto, Toshihiro
AU  - Miyamoto T
AD  - Department of Medicine and Biosystemic Science, Kyushu University Graduate School 
      of Medical Sciences, Fukuoka, Japan.
FAU - Egashira, Nobuaki
AU  - Egashira N
AD  - Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan.
FAU - Nakamura, Tsutomu
AU  - Nakamura T
AD  - Education and Research Center for Clinical Pharmacy, Osaka University of 
      Pharmaceutical Sciences, Osaka, Japan.
FAU - Akashi, Koichi
AU  - Akashi K
AD  - Department of Medicine and Biosystemic Science, Kyushu University Graduate School 
      of Medical Sciences, Fukuoka, Japan.
FAU - Ieiri, Ichiro
AU  - Ieiri I
AD  - Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 04079A1RDZ (Cytarabine)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - Q20Q21Q62J (Cisplatin)
RN  - X4W7ZR7023 (Methylprednisolone)
SB  - IM
EIN - Anticancer Res. 2022 Jun;42(6):3231-3232. PMID: 35641303
MH  - Adult
MH  - *Cisplatin/adverse effects
MH  - Cytarabine/adverse effects
MH  - Etoposide/adverse effects
MH  - Humans
MH  - *Lymphoma, Non-Hodgkin/drug therapy
MH  - Methylprednisolone/therapeutic use
OTO - NOTNLM
OT  - Chemotherapy
OT  - ESHAP+/-R therapy
OT  - adverse events
OT  - medication guidance sheet
OT  - non-Hodgkin's lymphoma
EDAT- 2022/03/30 06:00
MHDA- 2022/04/05 06:00
CRDT- 2022/03/29 05:44
PHST- 2022/01/16 00:00 [received]
PHST- 2022/03/09 00:00 [revised]
PHST- 2022/03/10 00:00 [accepted]
PHST- 2022/03/29 05:44 [entrez]
PHST- 2022/03/30 06:00 [pubmed]
PHST- 2022/04/05 06:00 [medline]
AID - 42/4/2053 [pii]
AID - 10.21873/anticanres.15686 [doi]
PST - ppublish
SO  - Anticancer Res. 2022 Apr;42(4):2053-2060. doi: 10.21873/anticanres.15686.